<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02063022</url>
  </required_header>
  <id_info>
    <org_study_id>ISG/AIEOP EW-1</org_study_id>
    <nct_id>NCT02063022</nct_id>
  </id_info>
  <brief_title>Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma</brief_title>
  <acronym>EW-1</acronym>
  <official_title>Phase III Study on Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Italian Sarcoma Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Italian Sarcoma Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Controlled, randomized phase III study, with the intent of optimizing the treatment of not&#xD;
      metastatic Ewing Sarcoma. The patients will be randomized into 2 arms: standard treatment vs&#xD;
      intensive treatment. Both arms will receive an induction treatment followed by surgery&#xD;
      (wherever is possible) and/or radiotherapy. The maintenance treatment will be different on&#xD;
      the basis of the response to the induction treatment (good or poor)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients with non metastatic Ewing's Sarcoma will be randomized into 2 different&#xD;
      arms: standard treatment arm A (based on the ISG/SSG III protocol) or into the experimental&#xD;
      arm B(chemotherapy with dose intensification and shorter length of treatment).&#xD;
&#xD;
      Both arm will receive an induction treatment with higher dose intensity of doxorubicin and&#xD;
      ifosfamide in Arm B.&#xD;
&#xD;
      After the induction treatment all the patient will undergo to local treatment (surgery and/or&#xD;
      radiotherapy)that will be followed by a maintenance therapy.&#xD;
&#xD;
      The maintenance therapy will be different for both arms and, within each arm, on the basis of&#xD;
      the response (histologically evaluated) of the pre-local treatment therapy.&#xD;
&#xD;
      Maintenance for Arm A: Poor responders will undergo to stem cells apheresis and their&#xD;
      reinfusion after treatment with high doses of Busulfan and Melphalan 25 weeks.&#xD;
&#xD;
      Good responders will receive a 6 drugs maintenance treatment for 37 weeks (as per standard&#xD;
      ISG/SSG III protocol)&#xD;
&#xD;
      Maintenance for Arm B: Poor responders will undergo to stem cells apheresis and their&#xD;
      reinfusion after an intensified treatment with high doses of Busulfan and Melphalan (25&#xD;
      weeks).&#xD;
&#xD;
      Good responders will receive a maintenance treatment for 25 weeks&#xD;
&#xD;
      The primary aim of the study is to assess the Event Free Survival (EFS) that is expected to&#xD;
      be similar in both arms&#xD;
&#xD;
      The secondary objectives are:&#xD;
&#xD;
      To assess if the induction treatment in Arm B is able to increase the percentage of good&#xD;
      responders compared to those who receive standard treatment.&#xD;
&#xD;
      To assess the toxicity and the Quality of Life related to the chemotherapy treatment&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 22, 2009</start_date>
  <completion_date type="Anticipated">December 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event Free Survival (EFS)</measure>
    <time_frame>5 years</time_frame>
    <description>The EFS (event defined as Progressive Disease , onset of local relapse and/or metastasis, death due to chemotherapy toxicity or for other causes) will be calculated from the first treatment day up to the event onset or to last follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival (DFS)</measure>
    <time_frame>expected average 3 years</time_frame>
    <description>The DFS will be calculated from the day that the patient will be free from disease (surgery date and/or radiotherapy completion) up to the date of progression disease or last follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metastasis Free Survival</measure>
    <time_frame>expected average 2 years</time_frame>
    <description>The Metastasis free Survival will be evaluated from the time of disease free (surgery performed and/or radiotherapy completed) to the onset of distance metastasis or last follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>expected average 5 years</time_frame>
    <description>The OS will be evaluated for the start treatment day to the day of death (for any causes)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">242</enrollment>
  <condition>Ewing's Sarcoma</condition>
  <arm_group>
    <arm_group_label>Standard treatment (as per ISG SSG III protocol)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard treatment for non metastatic Ewing's Sarcoma (as defined by the ISG/SSG III protocol).&#xD;
It is based on a 6 drugs pre-local treatment (Vincristin, dactinomycin, cyclophosphamide,ifosfamide,etoposide and doxorubicin) followed by local treatment (surgery and/or radiotherapy)and by a maintenance treatment based on induction response</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intensified treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose intense treatment for non metastatic Ewing's Sarcoma It is based on a 3 drug pre-local treatment (Vincristin, ifosfamide and doxorubicin)followed by local treatment (surgery and/or radiotherapy)and by a maintenance treatment based on induction response</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard treatment (as per protocol ISG SSG III)</intervention_name>
    <description>Induction treatment with: 4 cycle of Vincristine (9mg/,2), Dactinomycin (6mg/m2), Doxorubicin (160mg/m2), Cyclophosphamide (2.4g/m2), Ifosfamide (18g/M2) and Etoposide (450mg/m2) given every 3 weeks Maintenance treatment for poor responder (25 weeks): Vincristine (12mg/m2), Dactinomycin (1.5mg/m2), Doxorubicin (320mg/m2), Ifosfamide (27g/m2), Cyclophosphamide (8.8g/m2), Etoposide (1.5g/m2) and peripheral Cells Steam Transplant after Busulfan and Melphalan treatment Maintenance treatment (37 week) for good responder: Vincristine (18mg/m2), Dactinomycin (6mg/m2), Doxorubicin (400mg/m2), Ifosfamide (72g/m2), Cyclosphosphamide(6g/m2), Etoposide (1.8 g/m2)</description>
    <arm_group_label>Standard treatment (as per ISG SSG III protocol)</arm_group_label>
    <other_name>Vincristine</other_name>
    <other_name>Dactinomycin</other_name>
    <other_name>Doxorubicin</other_name>
    <other_name>Ifosfamide</other_name>
    <other_name>Cyclophosphamide</other_name>
    <other_name>Etoposide</other_name>
    <other_name>Busulfan</other_name>
    <other_name>Melphalan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intensified chemotherapy</intervention_name>
    <description>Induction treatment with: 4 cycle of Vincristine (10.5 mg/m2), Doxorubicin (320 mg/m2) and Ifosfamide (36 mg/m2) given every 3 weeks&#xD;
Maintenance treatment for poor responder (25 weeks): Vincristine (12mg/m2), Doxorubicin (400mg/m2), Ifosfamide (63g/m2), Cyclophosphamide (4g/m2), Etoposide (1.5g/m2) and Cells Steam Transplant after Busulfan and Melphalan treatment&#xD;
Maintenance treatment (25 week) for good responder: Vincristine (12mg/m2), Doxorubicin (400mg/m2), Ifosfamide (72g/m2), Etoposide (1.8g/m2)</description>
    <arm_group_label>Intensified treatment</arm_group_label>
    <other_name>Vincristine,</other_name>
    <other_name>Doxorubicin</other_name>
    <other_name>Ifosfamide</other_name>
    <other_name>Cyclophosphamide</other_name>
    <other_name>Etoposide</other_name>
    <other_name>Busulfan</other_name>
    <other_name>Melphalan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Ewing Sarcoma or PNET diagnosis centrally confirmed&#xD;
&#xD;
          -  Age â‰¤ 40 years&#xD;
&#xD;
          -  Absence of evident metastasis or lung met &lt; 0.5 cm Presence of skip metastasis in the&#xD;
             bone compartment of the primary tumor is to be considered as local disease and not&#xD;
             metastatic.&#xD;
&#xD;
          -  Adeguate bone marrow, hepatic and renal function&#xD;
&#xD;
          -  Left Ventricular Ejection Fraction &gt; 50%&#xD;
&#xD;
          -  No primary Ewing Sarcoma treatments (both chemotherapy and/or radiotherapy)&#xD;
&#xD;
          -  Voluntarily signed an informed consent form&#xD;
&#xD;
          -  Radiological and histological documentation available for central review.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Presence of lung or extra-pulmonary lesions&#xD;
&#xD;
          -  Bone Marrow involvement&#xD;
&#xD;
          -  In case of chest disease: presence of plural effusion&#xD;
&#xD;
          -  Elapsed time between histological diagnosis and chemotherapy start, more than 4 weeks&#xD;
&#xD;
          -  Any medical contraindication to the use of the study drugs&#xD;
&#xD;
          -  Any psychological or social conditions that can compromise the protocol compliance&#xD;
             and/or follow-up&#xD;
&#xD;
          -  Previous malignancies (excluded in situ cervix carcinoma)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roberto Luksch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Italian Sarcoma Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro di Riferimento Oncologico - Unit of Medical Oncology</name>
      <address>
        <city>Aviano</city>
        <state>Pordenone</state>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>I.R.C.C. - Unit of Medical Oncology</name>
      <address>
        <city>Candiolo</city>
        <state>Torino</state>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS materno infantile Burlo Garofolo</name>
      <address>
        <city>Trieste</city>
        <state>T</state>
        <zip>34137</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Consorziale Policlinico - Bari</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Ortopedico Rizzoli</name>
      <address>
        <city>Bologna</city>
        <zip>40136</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Meyer</name>
      <address>
        <city>Firenze</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Giannina Gaslini</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FONDAZIONE IRCCS Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria &quot;Federico Ii&quot; .</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori Regina Elena - Unit of Medical Oncology I</name>
      <address>
        <city>Roma</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambin Gesu'</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Infantile Regina Margherita - Unit of Paediatric Oncoematology</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.italiansarcomagroup.org/wp-content/uploads/2014/04/EW1.pdf</url>
    <description>Italian protocol Synopsis</description>
  </link>
  <reference>
    <citation>S. Ferrari, T. Alvegard, R. Luksch, A. Tienghi, K. S. Hall, G. Bernini, A. Brach del Prever, P. Picci, G. Bacci, S. Smeland Non-metastatic Ewing's family tumors: High-dose chemotherapy with stem cell rescue in poor responder patients. Preliminary results of the Italian/Scandinavian ISG/SSG III protocol. J Clini Oncol, 2007 ASCO Annual Meeting Proceedings Vol 25 (June 20 Suppl), 2007: 10014</citation>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 21, 2013</study_first_submitted>
  <study_first_submitted_qc>February 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2014</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non metastatic Ewing's Sarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Sarcoma, Ewing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dactinomycin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

